SUMMARY OF PRODUCT CHARACTERISITICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Progressis

Emulsion for injection for pigs (sows and gilts)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 2-ml dose of vaccine contains:

Active substance:

Inactivated Porcine Reproductive and Respiratory Syndrome (PRRS) virus,

P120 strain ...................................................................................≥ 2.5 log 10 IF* units.

*IF units: ImmunoFluorescence antibody titre obtained after 2 injections in pigs under specific laboratory conditions.

Adjuvant:

O/w oily excipient (containing hydrogenated polyisobutene as adjuvant) q.s. 1 dose of 2 ml.

Excipient(s):

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

White homogeneous emulsion for injection.

4. CLINICAL PARTICULARS

4.1 Target species

Pigs (sows and gilts).

4.2 Indications for use, specifying the target species

Reduction of the reproductive disorders caused by Porcine Reproductive and Respiratory Syndrome virus (European strain) in a contaminated environment: vaccination reduces the number of early farrowings and the number of still-births.

4.3 Contraindications

None

4.4 Special warnings for each target species

In PRRS infected herds, viral infection is heterogeneous and varies over time. In such context, the implementation of a vaccination program is a tool to improve the reproductive parameters and may contribute to the disease control in conjunction with sanitary measures.

Vaccinate healthy animals only.

4.5 Special precautions for use

Special precautions for use in animals

Apply usual procedures for the handling of animals

Special precautions to be taken by the person administering the veterinary medicinal product to animals

To the user:

This product contains mineral oil. Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.

If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you.

If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

4.6 Adverse reactions (frequency and seriousness)

Vaccination may induce a transient oedema (at most 3 cm) lasting generally less than one week and small local reaction (granulomas), without any effect on the health and the reproductive performance of the animal. Larger reactions (up to 7 cm diameter) have been observed occasionally after frequently repeated revaccinations. Vaccination may rarely cause hypersensitivity reactions. In such cases, an appropriate symptomatic treatment should be carried out.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of interaction

Data are available which demonstrate that this vaccine can be administrated on a same day in a separate site, with inactivated vaccines against parvovirosis, influenza and Aujeszky’s disease as no adverse effect on the serological response has been observed. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amounts to be administered and administration route

One dose of 2 ml is administered by deep intramuscular route, in the neck muscles behind the ear, according to the following vaccination scheme:

Primary vaccination:

Gilts:

2 injections 3-4 weeks apart, at least 3 weeks before mating.

Sows:

2 injections 3-4 weeks apart (vaccination of all the sows of the herd within a short period is recommended).

Revaccination:

One injection at 60-70 days of each gestation, as of the first gestation following the primary vaccination.

Apply usual aseptic procedures. The use of a multi-dosing syringe is recommended.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

After administration of a double dose, no adverse reactions other than those described in section 4.6 were observed.

4.11 Withdrawal period(s)

Zero days.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Immunologicals for suidae / Inactivated viral vaccines / porcine reproductive and respiratory syndrome (PRRS) virus. ATCvet code: QI09AA05

The vaccine contains inactivated PRRS virus in an oily adjuvant. It is intended to stimulate immunity against PRRS virus. The efficacy was demonstrated under field conditions during field trials. Whereas no effector immunomechanism on protection has been shown, the uptake of the vaccine has been demonstrated by the production of specific anti-PRRS IFA antibodies in vaccinated animals.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Hydrogenated polyisobutene

Polyoxyethylene fatty acids

Ether of fatty alcohols and of polyols

Benzyl alcohol

Triethanolamine

Potassium chloride

Sodium chloride

Potassium dihydrogen phosphate

Disodium phosphate dihydrate

Magnesium chloride

Calcium chloride

Water for injections

6.2 Major incompatibilities

Do not mix with any other veterinary medicinal product.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 18 months. Shelf life after first opening the vial: use immediately after opening.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Protect from light.

6.5 Nature and composition of immediate packaging

Nature of primary packaging elements:

- Type I glass bottle, LDPE bottle

- Nitril elastomer closure

- Aluminium cap

Packaging intended for sale:

- Box of 1 bottle of 5 doses / 10 ml glass bottle

- Box of 10 bottles of 5 doses / 10 ml glass bottle

- Box of 1 bottle of 10 doses / 20 ml glass bottle

- Box of 10 bottles of 10 doses / 20 ml glass bottle

- Box of 1 bottle of 25 doses / 50 ml glass bottle

- Box of 10 bottles of 25 doses / 50 ml glass bottle

- Box of 1 bottle of 50 doses / 100 ml LDPE bottle

- Box of 10 bottles of 50 doses / 100 ml LDPE bottle

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Ceva Animal Health Ltd

Explorer House

Mercury Park

Wycombe Lane

Wooburn Green

High Wycombe

Buckinghamshire

HP10 0HH

United Kingdom

8. MARKETING AUTHORISATION NUMBER

Vm 15052/4150

9. DATE OF FIRST AUTHORISATION

21 September 2000

10. DATE OF REVISION OF THE TEXT

October 2022

Approved: 12 October 2022